Skip to main content

Table 5 Outcomes in the cohort during the follow-up period of up to 23 years

From: Comparison of clinical outcomes in patients undergoing mitral valve replacement with mechanical or biological substitutes: a 20 years cohort

Variable

Sample (n = 352) n (%)

Mechanical prosthesis (n = 247) n (%)

Biological prosthesis (n = 105) n (%)

p

Reoperation for valve replacement

33 (9.4)

16 (6.5)

17 (16.2)

0.008

Bleeding events

23 (6.5)

18 (7.3)

5 (4.8)

0.521

Thromboembolic events

7 (2.0)

5 (2.0)

2 (1.9)

1.000

Total number of deaths

91 (25.9)

52 (21.1)

39 (37.1)

0.003

Perioperative death

21 (6.0)

10 (4.0)

11 (10.5)

0.037

ICU*

9 (2.6)

4 (1.6)

5 (4.8)

0.133

Hospital*

11 (3.1)

5 (2.0)

6 (5.7)

0.092

Others**

70 (19.9)

42 (17.0)

28 (26.7)

0.053

  1. ICU, intensive care unit; *none exceeded the perioperative period; **deaths after 30 days of hospitalization.
  2. A significantly higher incidence of reoperation for valve replacement (p = 0.008) and death (p = 0.003) was found in patients who underwent biological valve replacement (Table 5).